ClinicalTrials.gg
CompletedNCT00322348Updated Jan 24, 2011Results posted

Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

A Phase 2 interventional study of Goserelin acetate and Goserelin acetate in Advanced Breast Cancer, sponsored by AstraZeneca. Completed at 15 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Primary conditionBreast NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Breast Neoplasms
Why
  1. The study's listed conditions name Breast Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing goserelin in Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Goserelin · Breast Neoplasms.

Enrollment
24th of 41
98 · median 147
Started
2006
with 2 others
Phase 2
21 of 43
6 open now
Registered
9th of 43
by date
Lead sponsor
5 of 43
AstraZeneca

Among the 43 studies testing goserelin in Breast Neoplasms, this one is the 24th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2006, is one of 21 in phase 2, and was the 9th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 43 studies testing goserelin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About goserelin

Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing goserelin in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective is to evaluate whether Zoladex 10.8 mg (12-weekly) is non-inferior to Zoladex 3.6 mg (4-weekly) in pre-menopausal women with oestrogen receptor positive advanced breast cancer by assessment of progression-free survival at 24 weeks.

Secondary Objectives are to compare the safety and tolerability profile of ZOLADEX 10.8 mg and ZOLADEX 3.6 mg by assessment of adverse events (AEs)and to assess goserelin PK in Japanese and Caucasian participants who have received ZOLADEX 10.8 mg by assessment of goserelin plasma concentration time profiles

Recruitment into the study has been permanently stopped as of 24 December 2007 due to slow recruitment. 98 (vs the planned 260) patients were randomised into the study and will be followed as per protocol for 2 years

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • oncology
  • cancer
  • breast cancer
04

In context

Breast Neoplasms Reclassified

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

This study's enrollment of 98 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-menopausal women aged 18 years or over with histologically/-confirmed oestrogen receptor positive (ER +ve) breast cancer
  • World Health Organization (WHO) performance status of 0, 1, or 2
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Treatment with tamoxifen or other hormonal therapies as early breast cancer (EBC) adjuvant in the previous 24 weeks
  • Received radiotherapy within the past 4 weeks
  • History of systemic other than breast cancer within the previous 3 years
  • Estimated survival less than 24 weeks
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    ZOLADEX 10.8 mg

    ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks

    Drug: Goserelin acetate

  • Experimental
    ZOLADEX 3.6 mg

    ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks

    Drug: Goserelin acetate

Interventions

  • 3.6 mg intramuscular depot injection given every 4 weeks

    Also known as: Zoladex®

  • 10.8 mg intramuscular depot injection given every 12 weeks

    Also known as: Zoladex®

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Progression Free Survival (PFS) at Week 24

    The number of participants for whom neither objective disease progression or death (due to any cause) has been observed at Week 24 over the number of randomised participants x 100.

    Time frame: Objective tumour assessments carried out every 12 weeks (+/- 7 days) until Week 24, and then every 24 weeks (+/- 14 days) until Week 96 or objective progression is confirmed according to Response Evaluation Criteria in Solid Tumours (RECIST).

Secondary outcomes

  1. Objective Response Rate (ORR) at Week 24

    Number of participants who were objective responders at Week 24 over the number of participants evaluable for response x 100. An objective responder = a participants whose best unconfirmed response is either CR (Complete Response Disappearance of all target lesions) or PR (Partial Response At least a 30% decrease in target lesions)

    Time frame: Response Evaluation Criteria in Solid Tumours (RECIST) tumour assessments carried out every 12 weeks from randomisation until Week 24 in those patients with measurable disease at baseline.

  2. Oestradiol (E2) Serum Concentrations at Week 24

    A comparison of mean E2 serum concentrations at timepoint(s) post Day 1 performed using analysis of covariance (ANCOVA), with treatment group, baseline E2 serum concentrations and country as covariates. Data analysed on the log scale; log scale mean and pooled log scale standard deviation from Analysis of Covariance (ANCOVA) presented.

    Time frame: Blood samples for measurement of E2 concentrations collected from all patients at scheduled visits of screening, Day 1 and Weeks 12 and 24 (+/- 7 days). Week 24 data is presented

  3. Maximum Plasma Concentration, Cmax (ng/mL)

    Maximum plasma concentration, Cmax (ng/mL), derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)

    Time frame: Blood samples taken at Days 1, 2 and 3, Weeks 4, 12 and 24. Derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug for patients in the pharmacokinetic (PK) subgroup

  4. Time to Maximum Plasma Concentration, Tmax (Hours)

    Time to maximum plasma concentration, Tmax (hours), derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)

    Time frame: Blood samples taken at Days 1, 2 and 3, Weeks 4, 12 and 24. Derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug for patients in the pharmacokinetic (PK) subgroup

  5. Area Under the Plasma Concentration Curve (0-12 Weeks)

    Area under the plasma concentration curve (0-12 weeks) derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)

    Time frame: Blood samples taken at Days 1, 2 and 3, Weeks 4, 12 and 24. Derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug for patients in the pharmacokinetic (PK) subgroup

08

Results

Posted Jan 24, 2011
Limitations and caveats
The criteria for non-inferiority were not met for the primary efficacy endpoint (PFS at Week 24). However, since recruitment was terminated prematurely, the study was no longer adequately powered to detect non-inferiority.

Participant flow

Pre-menopausal women with Oestrogen Receptor Positive Advanced Breast Cancer were recruited between 25th April 2006 and 24th December 2007. 49 participants were randomised to ZOLADEX 10.8 mg and 49 participants were randomised to ZOLADEX 3.6 mg. One participant was randomised to ZOLADEX 3.6 mg but received ZOLADEX 10.8 mg.

Participant flow — Overall Study
MilestoneZOLADEX 10.8 mgZOLADEX 3.6 mg
Started4949
Received study treatment5048
Completed1216
Not completed3733
Withdrew: Adverse event01
Withdrew: Withdrawal by subject14
Withdrew: Lost to follow-up10
Withdrew: Death02
Withdrew: Disease progression3025
Withdrew: Reasons not specified51

Outcome measures

PrimaryPercentage of Participants With Progression Free Survival (PFS) at Week 24

The number of participants for whom neither objective disease progression or death (due to any cause) has been observed at Week 24 over the number of randomised participants x 100.

Time frame:
Objective tumour assessments carried out every 12 weeks (+/- 7 days) until Week 24, and then every 24 weeks (+/- 14 days) until Week 96 or objective progression is confirmed according to Response Evaluation Criteria in Solid Tumours (RECIST).
Reported as:
Number · Percentage of participants
Percentage of Participants With Progression Free Survival (PFS) at Week 24
Percentage of participantsZOLADEX 10.8 mgZOLADEX 3.6 mg
Percentage of Participants With Progression Free Survival (PFS) at Week 2469.473.5
SecondaryObjective Response Rate (ORR) at Week 24

Number of participants who were objective responders at Week 24 over the number of participants evaluable for response x 100. An objective responder = a participants whose best unconfirmed response is either CR (Complete Response Disappearance of all target lesions) or PR (Partial Response At least a 30% decrease in target lesions)

Time frame:
Response Evaluation Criteria in Solid Tumours (RECIST) tumour assessments carried out every 12 weeks from randomisation until Week 24 in those patients with measurable disease at baseline.
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) at Week 24
Percentage of participantsZOLADEX 10.8 mgZOLADEX 3.6 mg
Objective Response Rate (ORR) at Week 2428.925.6
SecondaryOestradiol (E2) Serum Concentrations at Week 24

A comparison of mean E2 serum concentrations at timepoint(s) post Day 1 performed using analysis of covariance (ANCOVA), with treatment group, baseline E2 serum concentrations and country as covariates. Data analysed on the log scale; log scale mean and pooled log scale standard deviation from Analysis of Covariance (ANCOVA) presented.

Time frame:
Blood samples for measurement of E2 concentrations collected from all patients at scheduled visits of screening, Day 1 and Weeks 12 and 24 (+/- 7 days). Week 24 data is presented
Reported as:
Log mean · pmol/L
Oestradiol (E2) Serum Concentrations at Week 24
pmol/LZOLADEX 10.8 mgZOLADEX 3.6 mg
Oestradiol (E2) Serum Concentrations at Week 241.42 ± 0.991.49 ± 0.99
SecondaryMaximum Plasma Concentration, Cmax (ng/mL)

Maximum plasma concentration, Cmax (ng/mL), derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)

Time frame:
Blood samples taken at Days 1, 2 and 3, Weeks 4, 12 and 24. Derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug for patients in the pharmacokinetic (PK) subgroup
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration, Cmax (ng/mL)
ng/mLZOLADEX 10.8 mgZOLADEX 3.6 mg
Maximum Plasma Concentration, Cmax (ng/mL)4.565 (0.501 to 14.000)—
SecondaryTime to Maximum Plasma Concentration, Tmax (Hours)

Time to maximum plasma concentration, Tmax (hours), derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)

Time frame:
Blood samples taken at Days 1, 2 and 3, Weeks 4, 12 and 24. Derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug for patients in the pharmacokinetic (PK) subgroup
Reported as:
Geometric mean · hours
Time to Maximum Plasma Concentration, Tmax (Hours)
hoursZOLADEX 10.8 mgZOLADEX 3.6 mg
Time to Maximum Plasma Concentration, Tmax (Hours)1.9 (1 to 24)—
SecondaryArea Under the Plasma Concentration Curve (0-12 Weeks)

Area under the plasma concentration curve (0-12 weeks) derived from analysis of pharmacokinetic (PK) outcomes samples provided only by participants in the PK subgroup set (all of whom received ZOLADEX 10.8 mg)

Time frame:
Blood samples taken at Days 1, 2 and 3, Weeks 4, 12 and 24. Derived from the individual goserelin plasma concentration-time profiles following the first dose of study drug for patients in the pharmacokinetic (PK) subgroup
Reported as:
Geometric mean · ng/mL
Area Under the Plasma Concentration Curve (0-12 Weeks)
ng/mLZOLADEX 10.8 mgZOLADEX 3.6 mg
Area Under the Plasma Concentration Curve (0-12 Weeks)33.021 (9.13 to 73.70)—

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZOLADEX 10.8 mg—2/50 (4%)39/50 (78%)
ZOLADEX 3.6 mg—3/48 (6.3%)37/48 (77.1%)
Most frequent serious events
Most frequent serious events
EventZOLADEX 10.8 mgZOLADEX 3.6 mg
Peritonsillar AbscessInfections and infestations0/501/48
Endometrial HyperplasiaReproductive system and breast disorders1/501/48
HaematomaVascular disorders0/501/48
Humerus FractureInjury, poisoning and procedural complications1/500/48
Most frequent other events
Showing 10 of 17
Most frequent other events
EventZOLADEX 10.8 mgZOLADEX 3.6 mg
Hot FlushVascular disorders19/5018/48
AmenorrhoeaReproductive system and breast disorders13/5011/48
NasopharyngitisInfections and infestations11/505/48
Weight IncreasedInfections and infestations7/508/48
NauseaGastrointestinal disorders3/504/48
FatigueGeneral disorders0/504/48
PyrexiaGeneral disorders1/504/48
ArthralgiaMusculoskeletal and connective tissue disorders2/504/48
CoughRespiratory, thoracic and mediastinal disorders0/504/48
HeadacheNervous system disorders4/503/48

Baseline characteristics

Age Continuous
Age Continuous(Years)ZOLADEX 10.8 mgZOLADEX 3.6 mgTotal
Mean42.0 ± 6.4542.6 ± 6.0742.3 ± 6.24
Sex: Female, Male
Sex: Female, Male(Participants)ZOLADEX 10.8 mgZOLADEX 3.6 mgTotal
Female494998
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ZOLADEX 10.8 mgZOLADEX 3.6 mgTotal
Caucasian273259
Black000
Oriental221739
Other000
09

Study locations

15 sites
  • Research Site
    Praha 8, Czech Republic
  • Research Site
    Arkhangelsk, Russian Federation
  • Research Site
    Belgorod, Russian Federation
  • Research Site
    Kaliningarad, Russian Federation
  • Research Site
    Kazan, Tatarstan, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    Ryazan, Russian Federation
  • Research Site
    St Petersburg, Russian Federation
  • Research Site
    St-petersburg, Russian Federation
  • Research Site
    Yaroslavl, Russian Federation
  • Research Site
    Dnipropetrovsk, Ukraine
  • Research Site
    Donetsk, Ukraine
  • Research Site
    Kharkiv, Ukraine
  • Research Site
    Odessa, Ukraine
  • Research Site
    Uzhgorod, Ukraine
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2006
First posted
May 5, 2006
Start
Apr 2006
CompletionActual
Nov 2009
Results first posted
Jan 24, 2011
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00322348
Lead sponsor
AstraZeneca
First posted
May 5, 2006
Start date
Apr 2006
Completion
Nov 2009
Results posted
Jan 24, 2011
Last update
Jan 24, 2011

Study contacts

Breast Cancer Established Brands Team Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goserelin

Start the discussion